Insilico Medicine has forged an external licensing and global R&D collaboration pact with Eli Lilly, a deal valued at up to roughly US$2.75 billion, encompassing an initial payment of US$115 million. This partnership employs a hybrid approach, combining "exclusive pipeline licensing" with "joint R&D." The licensed pipelines are likely to concentrate on the metabolic disease domain, fostering a profound strategic alliance between the two entities. The collaboration kicked off with a software subscription in 2023 and has progressively deepened, with the anticipation of a strategic symbiosis by 2026, driven by Insilico Medicine's ever-evolving Pharma.AI platform. By 2025, Insilico Medicine has constructed a diversified business development portfolio, accelerating its post-IPO business development trajectory while continually unlocking value from previous projects. With its AI platform as the cornerstone, Insilico Medicine has realized both technological and pipeline value, affirming the genuine worth of AI-driven drug discovery and reshaping the value realization paradigm in this sector, showcasing immense potential for the future.